News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.
Photo taken from Rami Manochakian/Twitter
Oct 4, 2023, 17:57

Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.

Rami Manochakian, Associate Professor and Hematology/Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:

“Hot off the press.

Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative Exclaim2 trial.”

 

Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.

For deteils click here.
Source: Rami Manochakian/Twitter

cancer Lung cancer Mayo Clinic Mobocertinib OncoDaily Oncology Rami Manochakian
Special Coverage
Opinion
Aug 24, 2025, 05:05
Naveen Pemmaraju: Wonderful to Meet Friends and Colleagues at MPN meeting 2025
Insight
Aug 24, 2025, 04:55
Shilpa Gupta Shared Highlights from IBCG 2025
Voices
Aug 24, 2025, 03:00
Giuseppe Minniti: Gliofocus Phase 3 Trial Explores PARP Inhibitors with Radiotherapy in GBM
Voices
Aug 24, 2025, 01:32
Minhua Chu: Zelgen Biopharma’s ZGGS34 Gets FDA Approval for Solid Tumor Study
Insight
Aug 24, 2025, 01:13
Discovering Approaches to Enhance CAR-NK Cell Antitumor Activity with CRISPR - MD Anderson Cancer Center
Voices
Aug 23, 2025, 23:27
Lauren Kriger Groner: Filming the Cracking Cancer Podcast with The White Ribbon Project
Voices
Aug 23, 2025, 22:57
Paolo Tarantino: Exploring IO and ADC Combinations at SITC25
Drugs
Aug 23, 2025, 22:35
LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen
Voices
Aug 23, 2025, 22:10
Neeraj Agarwal: USPCCC 2025 with Alan H Bryce's Introductory Remarks
Voices
Aug 23, 2025, 21:58
Al-Ola A Abdallah: Reducing Platelet Transfusion Threshold Before LP in Hematologic Malignancy Patients
Voices
Aug 23, 2025, 21:42
Nina Niu Sanford: NRG-GI011 Has Enrolled and Randomized Its 1st Patient
Voices
Aug 23, 2025, 21:31
Rahul Banerjee Shared NEJM Study on Targeted Therapy of CAR+ T-Cell Lymphoma